Purpose Breast conservation therapy (BCT) is standard for T1-T2 tumors, but early trials excluded breast cancers > 5 cm. This study was performed to assess patterns and outcomes of BCT for T3 tumors. Methods We reviewed the National Cancer Database (NCDB) for noninflammatory breast cancers > 5 cm, between 2004 and 2011 who underwent BCT or mastectomy (Mtx) with nodal evaluation. Patients with skin or chest wall involvement were excluded. Patients having clinical T3 tumors were analyzed to determine outcomes based upon presentation, with those having pathologic T3 tumors, subsequently assessed, irrespective of presentation. Overall survival (OS) was analyzed using multivariable Cox proportional hazards models, with adjusted survival curves estimated using inverse probability weighting. Results After exclusions, 37,268 patients remained. Median age and tumor size for BCT versus Mtx were 53 versus 54 years (p < 0.001) and 6.0 versus 6.7 cm (p < 0.001), respectively. Predictors of BCT included age, race, location, facility type, year of diagnosis, tumor size, grade, histology, nodes examined and positive, and administration of chemotherapy and radiotherapy. OS was similar between Mtx and BCT (p = 0.36). This held true when neoadjuvant chemotherapy patients were excluded (p = 0.39). BCT percentages declined over time (p < 0.001), while tumor sizes remained the same (p = 0.77). Median follow-up was 51.4 months. Conclusions OS for patients with T3 breast cancers is similar whether patients received Mtx or BCT, confirming that tumor size should not be an absolute BCT exclusion. Declining use of BCT for tumors > 5 cm in younger patients may be accounted for by recent trends toward mastectomy.
Introduction
Breast conservation therapy (BCT) has become a desirable alternative to mastectomy (Mtx) for women with early breast cancer since the 1980s. These procedures have become standard of care [1] and provide equivalent outcomes to mastectomy when accompanied by radiotherapy [2] . Breast conservation surgery is typically a shorter procedure, can be scheduled more quickly for operation [3] , and has psychological benefits over mastectomy [4] . These advantages have made this the standard of care, and rates of breast conservation are even now a quality measure for women having early stage breast cancer [5] .
Early studies only included tumors up to 5 cm [6] [7] [8] [9] , out of an abundance of caution because it has long been known that as tumor sizes increase, so do local recurrence rates [7] . Breast conservation also spares the breast, but disfigurement caused by an unfavorable breast-to-tumor ratio when treating larger tumors is felt to obviate any benefit of BCT. Because of this, tumor size greater than 5 cm has remained a relative contraindication to BCT as suggested by NCCN guidelines [1] . There are, however, data to suggest that BCT is feasible and safe for tumors > 5 cm.
Previous data have shown that there is no difference in disease-specific survival between BCT and mastectomy for tumors over 5 cm in the Medicare population [10] . That cohort of 5685 patients was limited to those over 65, however, and we are not aware of any published literature that attempts to reproduce this analysis in a broader population of women. We therefore proceeded with this current study, using a larger, more diverse patient population from the National Cancer Database (NCDB). This investigation was performed to determine whether the overall survival (OS) conferred by BCT was similar to Mtx for noninflammatory T3 breast cancer primaries. This study was also performed to assess trends in the USA for the performance of breast conservation in this group where it has traditionally been considered contraindicated.
Materials and methods
We queried the National Cancer Database (NCDB) for breast cancers > 5 cm diagnosed between 2004 and 2011, to provide adequate follow-up, who underwent BCT or Mtx. Male patients were excluded, as BCT is still not considered standard in this patient population. Histology codes were utilized to exclude Paget's disease and in situ carcinomas. Patients with unknown tumor size, carcinomas labeled as "diffuse," inflammatory cancers, and distant metastases were also excluded. Patients who received neoadjuvant chemotherapy were included, although neoadjuvant endocrine therapy or preoperative radiation therapy was excluded.
Clinical T3 (cT3) and pathologic T3 (pT3) tumors were reviewed to assess different objectives. cT3 tumors were used to determine predictors of BCT for tumors > 5 cm as clinical stage determines treatment options. pT3 stage was utilized for survival analysis as final pathology is related to outcomes.
We excluded patients who did not undergo nodal evaluation, or for whom nodal status was not recorded, as this information is critical for survival analysis. Intervals > 365 days from the time of diagnosis to surgery, which can affect survival [11] , and patients who did not undergo surgery were also excluded (Fig. 1) .
Sensitivity analyses were performed to determine overall survival of BCT versus Mtx with patients receiving neoadjuvant chemotherapy excluded to eliminate any possible selection bias and confounding on survival. An additional sensitivity analysis was also performed by including pathologic T3 cases that were also clinically T3, to assess clinically accurate T3 lesions.
Age, tumor size, and nodal status were treated as continuous variables, while all others were categorical. Chisquared and Wilcoxon rank sum tests were used to compare groups. Multivariable logistic regression was used to identify predictors of BCT based on patient, tumor, and 
Results
After all exclusions, there were 37,268 patients fulfilling criteria for analysis (Fig. 1 Patients less likely to undergo BCT included those who had a second cancer (OR 0.715, 95% CI 0.600-0.852, p = 0.001), and those who did not receive adjuvant radiation (OR 0.259, 95% CI 0.228-0.294, p < 0.001). Age < 45, greater number of lymph nodes examined and positive, geographic location outside of New England, lobular histology, year of diagnosis, and treatment at a comprehensive cancer center program were also less likely to receive BCT ( Table 2 ).
The year of diagnosis predicted whether patients underwent BCT, declining from 17.5% in 2004 to 15% in 2011 (p = 0.001) with 2010 having the lowest overall proportion of patients (13.5%) (Supplemental Table 1 ). However, the mean tumor size did not significantly change from 2004 to 2011 (trend p = 0.22) (Fig. 2) . Over time, the use of BCT decreased in the < 65 age group (p < 0.001), whereas in the > 65 age group, it was not significantly different over time (trend p = 0.288) (Fig. 3) .
There was no significant difference in OS of pT3 patients when comparing BCT to Mtx (p = 0.163). When adjusting for all of the characteristics listed in Table 2 , OS of pT3 patients was still equivalent (HR 0.963, 95% CI 0.889-1.043, p = 0.357) between BCT and Mtx (Supplemental Table 2 ). The 5-year adjusted OS for BCT was 68% (95% CI 0.652-0.709) and 69% for Mtx (95% CI 0.686-0.700), p = 0.63 (Fig. 4) .
When restricting the analysis to patients who were both clinically and pathologically T3, OS again remained unchanged (HR 0.963, 95% CI 0.850-1.090, p = 0.551). Finally, when removing patients who received neoadjuvant chemotherapy (a total of 6424 patients) from the analysis, the survival for pT3 patients who received either Mtx or BCT still did not differ (HR 1.039, 95% CI 0.951-1.136, p = 0.393) (Supplemental Table 2 , Fig. 5 ).
Discussion
As the current standard of care for early stage breast cancer, breast conservation has gained wide acceptance since its introduction in the early 1970s [12] . Its application has been cautioned for tumors > 5 cm because early trials, while widely varied, only included tumors 5 cm or smaller. Nevertheless, all of these studies found BCT equivalent to mastectomy, such as NSABP B-06, which limited patients to tumors > 2 and < 4 cm [13] , as versus EORTC 10,801, which included tumors up to 5 cm [9] . The Danish Cooperative Group included primaries > 3 cm in 7% of the cohort and found an 18% locoregional recurrence rate overall with no difference in OS [14] . Obedian and Haffty did not exclude T3 tumors, but these comprised only 1% of their patients. Still, they also found equivalent relapse-free and OS with negative or close margins [15] . These studies suggested that there is no difference in how larger tumors should be treated, but with none of these analyses powered to evaluate the T3 subgroup, no conclusion can be gleaned from these data. We have now shown, in a large diverse cohort, that BCT confers similar survival to that of Mtx for tumors not previously considered amenable to breast conservation.
Large retrospective series have found that overall survival is inversely proportional to tumor size, which likely impelled exclusion of large tumors in breast conservation trials [16] . We now know that survival is equivalent for smaller tumors treated by BCT versus Mtx, and there is no biological basis for the arbitrary cutoff of 5 cm. Similarly, several small studies have shown the feasibility of BCT for large tumors in terms of overall and disease-free survival, with neoadjuvant chemotherapy excluded from those analyses [17, 18] . These findings are consistent with ours here, showing equivalent OS between the two treatment approaches, even when controlling for neoadjuvant chemotherapy, although these studies were small retrospective reviews [17, 18] . A study by Khanna and colleagues, for example, found actuarial 5-year OS of 76% and actuarial disease-free survival rates of 68% in tumors > 4 cm, and no recurrences in patients with negative margins achieved. This coincides with our findings of an adjusted 5 year OS in pT3 patients of 68%. Although our data show that breast conservation for larger tumors is safe, there was a trend toward mastectomy in younger women over time. Recent studies have similarly found that mastectomy rates in BCT-eligible patients have been increasing since at least 2004 [19] [20] [21] . Additionally, rates of bilateral mastectomy for unilateral disease have increased in the absence of factors increasing oncologic risk, with young age as an independent predictor of mastectomy use [22] . This trend may be related to a greater recognition of higher recurrence in younger age groups and its influence on clinical decision-making [23] , but it should be noted that survival in young women (< 40) is not different when treated via BCT versus Mtx [23] . This is also likely to be driven by increasing patient involvement and changing patient preferences [24] .
Although the trend for BCT rates for tumors > 5 cm in patients > 65 years of age visually appears to decline over time in Fig. 2 , this was not statistically significant. It remains unknown why this differs from previously published SEERMedicare data for women ≥ 65 showing a steady increase in BCT procedures for T3 lesions over time [10] . Meanwhile, women ≤ 65, who were not previously analyzed, had a significant decrease in BCT procedures for T3 primaries in this study. It is impossible to determine what factors would cause these variations, but both datasets do consistently find that the majority of patients with T3 tumors still undergo mastectomy [10] as expected based upon current guidelines, such as the NCCN [1] , and the previous paucity of data supporting its safety. Our data also suggest a selection bias toward Mtx for more aggressive tumors, shown here by a higher number of lymph nodes examined, greater numbers of positive nodes, and larger tumor sizes in the Mtx group. Although we do not provide benefit when varying the breast procedure based upon nodal status, this may reflect clinicians' underlying desire to be more "aggressive" in the setting of negative independent predictors of survival [16] .
Also consistent with the SEER-Medicare published data on this topic, neoadjuvant chemotherapy use predicted BCT in patients having T3 tumors [10] . While we know that use of neoadjuvant chemotherapy (as vs. adjuvant chemotherapy) does not affect overall survival, it does potentially downstage the primary tumor and increase the likelihood of breast conservation [25] . This study indicates that the majority of tumors > 5 cm continue to be treated with chemotherapy prior to surgery, with 66% of BCT patients having received chemotherapy in the neoadjuvant setting. Still, our sensitivity Although we were unable to evaluate recurrence rates because the NCDB does not include such data, we know from the Early Breast Cancer Trialists' Collaborative Group metaanalysis that recurrence and survival are linked [26] . The similar OS found here therefore suggests that if any disease-specific survival (DSS) difference exists between BCT and Mtx for T3 tumors, the difference should be small. Moreover, a prior study in a different large dataset (SEER-Medicare) has confirmed in that sizable, but smaller national cohort, there is no difference in DSS for T3 tumors undergoing BCT as versus Mtx [10] .
Although this was not the focus of this study, a limitation of large datasets, like the NCDB, is the inability to judge cosmetic outcomes. There is some evidence to show that a good cosmetic appearance is feasible in BCT for T3 primaries, and recent oncoplastic techniques may provide more opportunities for cosmetically pleasing local resection of larger tumors. One such study evaluated 540 patients who underwent breast conservation for large tumor-to-breast ratio and found that oncoplastics provided a "good" cosmetic outcome based on a five point grading scale in 97.7% of patients. The study patients' disease-free survival and OS were also 87.9% and 92.9%, respectively, showing that safety was not compromised for cosmesis [27] . Another small study utilizing oncoplastic surgery with contralateral reduction mammoplasty found that these enabled larger resections, good cosmetic outcomes, and acceptable 5-year survival and local recurrence rates. Oncoplastic techniques have gained refinement and popularity and may even allow patients having T3 lesions and smaller or borderline breast sizes to undergo breast conservation successfully.
In conclusion, BCT for tumors > 5 cm is safe and has an equivalent OS to that of mastectomy. Although this study shows slightly declining use of breast conservation for larger tumors in recent years, practitioners should consider BCT based upon projected cosmetic outcomes and patient desires, and no longer consider BCT contraindicated solely based upon an arbitrary size cutoff.
